Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Gubra A/S is a biotechnology company specializing in preclinical contract research and peptide-based drug discovery, primarily targeting metabolic and fibrotic diseases. Headquartered in Hørsholm, Denmark, it focuses on the early stages of drug development, leveraging proprietary platforms like StreaMLine, AI, machine learning, and high-throughput screening to advance peptide therapeutics. The company's robust R&D pipeline spans metabolic, endocrine, fibrotic, inflammatory, CNS, respiratory, and women's health disorders, featuring internal programs such as urocortin-2 analogues for high-quality weight loss, dual orexin receptor agonists for narcolepsy, GLP-1 receptor agonists, and PTH receptor agonists for hypoparathyroidism. Gubra also collaborates with partners like AbbVie, Boehringer Ingelheim, and Amylyx Pharmaceuticals on obesity treatments, including amylin analogs and triple agonists in clinical stages. With operations emphasizing translational in vivo models and global presence, particularly in North America and the Nordic region, Gubra plays a key role in innovating therapies for chronic conditions like obesity, diabetes, and rare endocrine disorders.
DKK 43.34
DKK 0.80 (-1.81%)
Live · 10:05 PM · Twelve Data
Margins and capital returns are both well above average: 81.54% operating margin, ROIC at 187.41%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 892.2% YoY with margins expanding 100.4pp.
Even for strong businesses, today's 0x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
0.4x earnings, 0.4x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
DKK 2.64B
▲ +892.2% YoY
Net Income (TTM)
DKK 1.69B
▲ +4731.9% YoY
Op. Margin
81.54%
▲ +100.4pp YoY
ROIC
187.41%
▲ +194.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
DKK 1.69B
▲ +6348.2% YoY
Op. Cash Flow (TTM)
DKK 1.71B
▲ +8124.8% YoY
Net Debt
-DKK 976M
Net Cash Position
Cash & Equiv.
DKK 1.08B
3Y CAGR: +136.5%
3Y CAGR: +449.9%
Continue Research
At a P/E of 0.4 and a price-to-free-cash-flow of 0.4, Gubra A/S (GUBRA.XCSE) trades below a two-stage DCF intrinsic value of about DKK 5,302.17 per share, so at DKK 43.34 the stock looks undervalued (12,133.9% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Gubra A/S scores 98/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 141.6%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about DKK 5,302.17 per share for GUBRA.XCSE, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around DKK 3,976.63. At today's DKK 43.34, that puts the stock about 12,133.9% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Gubra A/S scores 98 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 81.5% operating margin and a 187.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Gubra A/S pays a regular dividend of about DKK 61.35 per share per year (typically in quarterly installments), a yield of roughly 141.6% at the current price. That is a payout ratio of about 59.2% of earnings, so the dividend is well covered. Gubra A/S has grown the dividend at roughly 432.3% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For GUBRA.XCSE's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. GUBRA.XCSE currently trades below its estimated intrinsic value and scores 98/100 on quality (high-quality). It also yields about 141.6%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.